Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | Head of Global Product Strat. | February 13, 2026 | February 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date February 13, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-02-13 | Direct | 7,390 |
Reported balance
After 2026-02-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-13 · Grant · Acquired 7,390 · Balance 7,390 F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 10, 2023 Filed Feb 15, 2023 02:41 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,515 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005271 · form4.xml · nonDerivative · entry 1 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,359 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 23:47 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 6,130 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-004578 · form4.xml · derivative · entry 2 Izzar Rachid · CIK 0001875506 · Head of Global Product Strat. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,130 Underlying: Common Stock · 6,130 shares Expires 2026-02-08 F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 02/08/2023. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 22:55 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 1,783 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-002481 · form4.xml · nonDerivative · entry 1 Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,844 F1 · shares: Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on February 12, 2020. The shares will vest on February 12, 2023. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 23:37 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 433 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-026993 · form4.xml · derivative · entry 7 Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 433 shares Expires 2022-12-02 F2 · date: This award was granted to the reporting person on December 2, 2019. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). F2 · derivative.exercise_date: This award was granted to the reporting person on December 2, 2019. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). F3 · derivative.exercise_date: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 23:37 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 425 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-026993 · form4.xml · derivative · entry 6 Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 433 Underlying: Common Stock · 425 shares Expires 2022-12-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This award was granted to the reporting person on December 2, 2019. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 23:37 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,285 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-026993 · form4.xml · derivative · entry 5 Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,285 shares Expires 2022-12-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This award was granted to the reporting person on December 2, 2019, and vested in full on December 2, 2022. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 23:37 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 189 | $298.90 | $56,492.10 |
DisclosureSEC source: 0001127602-22-026993 · form4.xml · nonDerivative · entry 4 Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,061 Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 23:37 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 425 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-026993 · form4.xml · nonDerivative · entry 3 Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 23:37 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 570 | $298.90 | $170,373.00 |
DisclosureSEC source: 0001127602-22-026993 · form4.xml · nonDerivative · entry 2 Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,825 Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 23:37 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-026993 · form4.xml · nonDerivative · entry 1 Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,395 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 23:28 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 504 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-019020 · form4.xml · derivative · entry 3 Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504 Underlying: Common Stock · 504 shares Expires 2024-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This award was granted to the reporting person on July 1, 2020, and will vest in three equal installments on each anniversary of the grant date. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 23:28 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 148 | $210.63 | $31,173.24 |
DisclosureSEC source: 0001127602-22-019020 · form4.xml · nonDerivative · entry 2 Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,110 Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 23:28 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 504 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-019020 · form4.xml · nonDerivative · entry 1 Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,258 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:16 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 854 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-006269 · form4.xml · derivative · entry 4 Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,902 Underlying: Common Stock · 854 shares Expires 2024-02-18 F2 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:16 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 594 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-006269 · form4.xml · derivative · entry 3 Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,756 Underlying: Common Stock · 594 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:16 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 175 | $209.79 | $36,713.25 |
DisclosureSEC source: 0001127602-22-006269 · form4.xml · nonDerivative · entry 2 Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,754 Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:16 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 594 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-006269 · form4.xml · nonDerivative · entry 1 Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,929 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:14 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 651 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004988 · form4.xml · derivative · entry 4 Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,006 Underlying: Common Stock · 651 shares Expires 2023-02-12 F2 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F3 · derivative.exercise_date: This award was granted to the reporting person on February 12, 2020. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:14 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 351 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004988 · form4.xml · derivative · entry 3 Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,657 Underlying: Common Stock · 351 shares Expires 2023-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:14 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 122 | $214.59 | $26,179.98 |
DisclosureSEC source: 0001127602-22-004988 · form4.xml · nonDerivative · entry 2 Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,335 Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:14 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 351 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004988 · form4.xml · nonDerivative · entry 1 Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,457 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:18 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 4,545 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004781 · form4.xml · derivative · entry 2 Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,545 Underlying: Common Stock · 4,545 shares Expires 2025-02-10 F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022. Read SEC document |
| December 02, 2021 Filed Dec 6, 2021 21:14 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 484 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-030351 · form4.xml · derivative · entry 4 Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 858 Underlying: Common Stock · 484 shares Expires 2022-12-02 F2 · kind: This number represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: This award was granted to the reporting person on December 2, 2019. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| December 02, 2021 Filed Dec 6, 2021 21:14 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 372 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-030351 · form4.xml · derivative · entry 3 Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,342 Underlying: Common Stock · 372 shares Expires 2022-12-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This award was granted to the reporting person on December 2, 2019. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| December 02, 2021 Filed Dec 6, 2021 21:14 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 165 | $228.52 | $37,705.80 |
DisclosureSEC source: 0001127602-21-030351 · form4.xml · nonDerivative · entry 2 Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,106 Read SEC document |
| December 02, 2021 Filed Dec 6, 2021 21:14 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 372 | $228.52 | $85,009.44 |
DisclosureSEC source: 0001127602-21-030351 · form4.xml · nonDerivative · entry 1 Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,271 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.